(NewsUSA) - The cancer treatment landscape is undergoing a profound shift. Patients, healthcare providers and advocates are seeking alternatives that deliver both clinical efficacy and quality of life. At the forefront of this movement is GentleCure™, a proven, noninvasive treatment for the most common type of cancer, nonmelanoma skin cancer. 

Dermatologists nationwide are reporting a surge in patient awareness of GentleCure. Patients are increasingly drawn to this Medicare-covered, nonsurgical therapy that allows them to maintain their normal routines without interruption. More than 125,000 patients have been treated with GentleCure across 400 dermatology practices, with thousands more receiving treatment each day. Notably, over 70 practices have introduced GentleCure just this year, a clear signal of its growing role in dermatology.  

Aaron S. Farberg, M.D., double board-certified dermatologist, Mohs surgeon, and editorial board member for leading medical journals, including Dermatology & Therapy and SKIN, affirms the trend. 

“At the five Texas practices for which I serve as Chief Medical Officer, we’ve seen a significant rise in patient demand for this noninvasive option,” Dr. Farberg notes. “While not every case of skin cancer is appropriate for GentleCure, thoughtful consultation with our board certified dermatologists ensures proper use and shared decision-making. For those treated, both the medical outcomes and patient satisfaction have been exceptional.” 

GentleCure harnesses Image-Guided Superficial Radiation Therapy (IGSRT), a state-of-the-art combination of technologies designed to treat basal cell and squamous cell carcinomas. 

Using low-level x-ray energy, GentleCure destroys cancer cells while sparing healthy tissue. The precision comes from high-resolution dermal ultrasound imaging, which maps the cancer in real time and enables the provider to deliver exactly the right dose. Quick and painless treatment delivery is repeated over several weeks, with minimal impact on a patients’ daily lives. 

The therapy’s success is supported by 17 clinical studies, which document cure rates exceeding 99 percent, matched by equally high patient satisfaction scores. 

Demographic trends are amplifying the need for noninvasive skin cancer care. As the  population ages and life expectancy rises, the incidence of skin cancer continues to climb, particularly among those with extensive sun exposure. Many older adults also face health conditions that make surgery riskier. 

The statistics are sobering: 9,500 Americans are diagnosed with skin cancer each day, adding up to more than 3 million new cases annually. Against this backdrop, GentleCure provides a safe, effective, and patient-friendly alternative that aligns with the realities of modern dermatology care. 

The growing adoption of GentleCure reflects a broader cultural and clinical shift toward noninvasive, patient-centered oncology care. As practices continue to embrace this technology, they expand their treatment capabilities and empower patients with choice, comfort, and confidence in their care journey. 

For more information, visit GentleCure.com